Interview with Igor Varlamov, CEO, Binnopharm
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Address: 124460, г. Москва, г. Зеленоград, 4-й Западный проезд, дом 3, строение 1,Russia
Tel: +7 (495) 510-3288
Closed Joint-Stock Company “Binnopharm” (Moscow, Zelenograd) is formed with a 100% charter capital belonging to JFC Sistema with investment volume more than 4.3 bln RUR (50% in CAPEX).
CJSC “Binnopharm” is CJSC “Binnopharm” with its productive area more than 32 thous м2 is one of the most large-scaled biopharmaceutical companies in Russia. Biotechnological and pharmaceutical complex “Binnopharm” has the largest in Russia biotech medicines manufacture with complete production cycle. Production is built according to GMP (Good Manufacturing Practice) quality standards. Company also has a unique biotech Research & Development center. “Binnopharm” complex is fully equipped with multipurpose production lines provided by top international players for the full-cycle production of biotech medicines like: tablets, capsules, ampoules, sprays and environment friendly aerosols.
Top-priority course for the company’s activities is focused on developing and commercial availability of medicines across socially significant diseases such as oncology, hematology, infections and respiratory ones, genetically engineered medicines, vaccines and fibroblast-tissue technologies’ products in regenerative medicine.
CJSC “Binnopharm” is the founder and the basis of the Moscow nanobiopharmaceutical cluster “Biocity” that is located on the territory of Moscow Special Economic Zone “Zelenograd” – industrial technology park specialized in developing and implementation of innovating medicines as well as allocation of the best western elaborations and technologies on the territory of Russia.
Activity of «Binnopharm» Company aims at production of innovative medical aids that meet GMP international standards and implementation of an import replacement program. Here are set production lines for releasing of basic dosage forms: pills, capsules, vials and ecologically safe aerosols. «Binnopharm» is also a distributor of pharmaceutical substances and off-the-shelf dosage forms.
Biotechnology and genetic engineering have special status in the activity of «Binnopharm» Company. The enterprise possesses a unique full-cycle biotechnological production in Russia, with the most integrated and equipped laboratory for biotechnological preparation quality control. Here is produced a vaccine against the viral Hepatitis B – Regevac B.
Vaccine «Regevac B» produced now by «Binnopharm» CJSC, as to its properties, meets the World Health Organization’s requirements, and it is not inferior to, and upon certain indicators – leaves behind the foreign analogs. It is the most efficient and expedient recombinant vaccine for use in the territory of the Russia, produced on the basis of Hepatitis B virus’ strain, serotype ay.
Basic therapeutic groups of preparations, the production of which is projected in the new «Binnopharm» complex, are: haematology, oncology, infectious diseases, and respiratory diseases. Underway is development of biotechnological preparations that have principally new therapeutic opportunities, including treatment of diseases incurable in the past (cancer, AIDS, disseminated sclerosis), as well as new transport nanoforms. The Company’s production line has been continuously expanding.
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here